Sign in Subscribe
Cancer research

Early Detection of Non-Small Cell Lung Cancer Through Cell-Free Circulating Tumor DNA

Strategic Insights

— 2 min read

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of all lung cancer cases worldwide. Unfortunately, most patients are diagnosed with NSCLC at an advanced stage, making treatment challenging. Recent studies have shown that cell-free circulating tumor DNA (ctDNA) in plasma or serum can serve as a potential tumor marker for early detection of NSCLC. This non-invasive and easily accepted method has shown promise in identifying patients with NSCLC, particularly those with at least one known gene abnormality.

Key Takeaways:

  • Cell-free circulating tumor DNA (ctDNA) in plasma or serum has been identified as a potential tumor marker for early detection of non-small cell lung cancer (NSCLC).
  • Studies have shown that the amount of ctDNA is significantly higher in NSCLC patients than in healthy controls or patients with benign diseases.
  • An association has been found between ctDNA levels and tumor stage, grade, lymph node involvement, number of metastatic sites, tumor response, and survival outcome.
  • Many genetic changes, such as gene mutation, loss of heterozygosity, microsatellite instability, and gene methylation, have been found in ctDNA in NSCLC patients.
  • These findings suggest that ctDNA could serve as a viable tool to monitor NSCLC and prompted the development of more sensitive and specific biomarkers for clinical practice.
  • Research has shown that ctDNA levels can be used to predict treatment response and survival outcome in patients with NSCLC.
  • The use of ctDNA as a diagnostic tool for NSCLC has the potential to improve patient outcomes by enabling early detection and treatment.

Statistics:

  • NSCLC accounts for more than 80% of all lung cancer cases worldwide (National Cancer Institute).
  • The-five-year survival rate for patients with NSCLC diagnosed at an early stage is around 50%, compared to less than 5% for those diagnosed at an advanced stage (American Cancer Society).
  • Studies have shown that the amount of ctDNA in plasma or serum is significantly higher in NSCLC patients than in healthy controls or patients with benign diseases (Tianjin University of Traditional Chinese Medicine, 2015).
  • The association between ctDNA levels and tumor stage, grade, lymph node involvement, number of metastatic sites, tumor response, and survival outcome has been found in multiple studies (e.g., Zhang et al., 2015).

Sources:

  • Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumor Biology, 2015;36(1):7-19. (Springer - www.springer.com; Tumor Biology - www.springerlink.com/content/1010-4283/)
  • National Cancer Institute. (2022). Lung Cancer (Non-Small Cell). Retrieved from
  • American Cancer Society. (2022). Lung Cancer. Retrieved from
  • Zhang et al. (2015). Circulating tumor DNA analysis of non-small cell lung cancer. Journal of Thoracic Oncology, 10(9), 1303-1312.

Read more